[go: up one dir, main page]

DE60035579D1 - Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme - Google Patents

Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme

Info

Publication number
DE60035579D1
DE60035579D1 DE60035579T DE60035579T DE60035579D1 DE 60035579 D1 DE60035579 D1 DE 60035579D1 DE 60035579 T DE60035579 T DE 60035579T DE 60035579 T DE60035579 T DE 60035579T DE 60035579 D1 DE60035579 D1 DE 60035579D1
Authority
DE
Germany
Prior art keywords
multiparticely
active ingredient
ssri
selective inhibitors
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60035579T
Other languages
English (en)
Other versions
DE60035579T2 (de
Inventor
Theresa Ann Jeary
Catherine Ann Morrissey
Paul Stark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE19990406A external-priority patent/IE990406A1/en
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Publication of DE60035579D1 publication Critical patent/DE60035579D1/de
Application granted granted Critical
Publication of DE60035579T2 publication Critical patent/DE60035579T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60035579T 1999-05-20 2000-05-10 Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme Expired - Lifetime DE60035579T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13502899P 1999-05-20 1999-05-20
US135028P 1999-05-20
IE19990406A IE990406A1 (en) 1999-05-20 1999-05-20 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IE990406 1999-05-20
PCT/IE2000/000060 WO2000071099A1 (en) 1999-05-20 2000-05-10 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations

Publications (2)

Publication Number Publication Date
DE60035579D1 true DE60035579D1 (de) 2007-08-30
DE60035579T2 DE60035579T2 (de) 2008-04-17

Family

ID=26320248

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035579T Expired - Lifetime DE60035579T2 (de) 1999-05-20 2000-05-10 Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme

Country Status (16)

Country Link
EP (2) EP1178780B1 (de)
JP (1) JP2003500348A (de)
AT (1) ATE367153T1 (de)
AU (1) AU782059B2 (de)
CA (2) CA2374039C (de)
CY (1) CY1107750T1 (de)
CZ (1) CZ302388B6 (de)
DE (1) DE60035579T2 (de)
DK (1) DK1178780T3 (de)
DZ (1) DZ3256A1 (de)
ES (1) ES2290027T3 (de)
HU (1) HU229569B1 (de)
PT (1) PT1178780E (de)
RU (1) RU2275191C2 (de)
SK (1) SK286865B6 (de)
WO (1) WO2000071099A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
BR0100334A (pt) * 2001-01-17 2002-09-24 Diffucap Chemobras Quimica E F Processo para a preparação de composições de liberação programada contendo venlafaxina e o produto resultante
IL161491A0 (en) * 2001-11-07 2004-09-27 Synthon Bv Tamsulosin tablets
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
DE60307819T2 (de) 2003-07-30 2007-10-04 Pharmathen S.A., Pallini Venlafaxine Hydrochloridformulierungen mit verzögerter Freisetzung
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
JP5153629B2 (ja) * 2005-08-02 2013-02-27 ルピン・リミテッド 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
JP2008231025A (ja) * 2007-03-20 2008-10-02 Kyowa Yakuhin Kogyo Kk マレイン酸フルボキサミン錠剤
WO2018206923A1 (en) * 2017-05-11 2018-11-15 Opal Ip Limited Novel formulations
WO2025111679A1 (pt) * 2023-11-30 2025-06-05 Prati, Donaduzzi & Cia Ltda Forma farmacêutica oral para liberação bifásica, composta por um sistema multiparticulado, processo para preparação da mesma e uso terapêutico da forma oral

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69020758T2 (de) * 1989-03-10 1995-12-07 Yamanouchi Pharma Co Ltd Die Wirkstoffabgabe steuerndes Überzugsmaterial für lang wirksame Formulierungen.
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
JPH0826977A (ja) * 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd 溶出制御型経口製剤
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
FR2754710B1 (fr) * 1996-10-22 1998-12-31 Prographarm Lab Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
ID23503A (id) * 1997-07-01 2000-04-27 Pfizer Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina
JP3786715B2 (ja) * 1997-07-01 2006-06-14 ファイザー・プロダクツ・インク セルトラリンの遅延放出剤形
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation

Also Published As

Publication number Publication date
AU4426700A (en) 2000-12-12
SK18962001A3 (sk) 2002-04-04
CA2698347A1 (en) 2000-11-30
JP2003500348A (ja) 2003-01-07
EP1178780A1 (de) 2002-02-13
DE60035579T2 (de) 2008-04-17
HUP0201884A2 (en) 2002-09-28
DZ3256A1 (fr) 2000-11-30
ATE367153T1 (de) 2007-08-15
CA2374039C (en) 2011-01-11
SK286865B6 (sk) 2009-06-05
EP1852111A1 (de) 2007-11-07
DK1178780T3 (da) 2007-11-12
HUP0201884A3 (en) 2006-07-28
CY1107750T1 (el) 2013-04-18
AU782059B2 (en) 2005-06-30
ES2290027T3 (es) 2008-02-16
CZ20014618A3 (cs) 2002-05-15
RU2275191C2 (ru) 2006-04-27
EP1178780B1 (de) 2007-07-18
PT1178780E (pt) 2007-10-25
CA2374039A1 (en) 2000-11-30
CZ302388B6 (cs) 2011-04-27
HU229569B1 (hu) 2014-02-28
WO2000071099A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
DE60121857D1 (de) Arzneimittelzusammensetzung mit verzögerter Wirkstoffabgabe
RS50924B (sr) Oralni dozni oblici propiverina ili njegovih farmaceutski prihvatljivih soli sa produženim oslobađanjem aktivne materije
DE60035579D1 (de) Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
DK0939626T3 (da) Galenisk form til forlænget frigivelse af milnacipran
CA2346001A1 (en) Controlled release nanoparticulate compositions
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
YU49495B (sh) Formulacije oksikodona sa kontrolisanim otpuštanjem i njihova upotreba
NO20022264L (no) Farmasoytisk blanding inneholdende tolterodin, samt anvendelse derav
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer&#39;s disease
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
ATE246505T1 (de) Zubereitung enthaltend cefaclor oder cephalexin mit modifizierter freisetzungsmatrix
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
EA200001201A3 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
GEP20043285B (en) Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
DE60042168D1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
DE69622739D1 (de) Pharmazeutische zubereitung mit schneller freisetzung
DE60006362D1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
CA2415154A1 (en) Modified release formulations of selective serotonin re-uptake inhibitors
CA2417887A1 (en) Particulate composition of eletriptan
DE60028730D1 (de) Multipartikuläre bisoprolol formulierung
UA74335C2 (uk) Мультичастинкова композиція контрольованого вивільнення флувоксаміну та спосіб лікування станів, які лікуються за допомогою селективних інгібіторів зворотного захоплення серотоніну

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ELAN PHARMA INTERNATIONAL LTD., ATHLONE, WESTM, IE